Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Marketing Status Prescription; Discontinued
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrial flutter02.03.03.0030.000808%
Atrial tachycardia02.03.03.0040.000202%
Atrioventricular block complete02.03.01.0030.000202%
Atrioventricular block first degree02.03.01.0040.001010%
Atrophic vulvovaginitis21.02.01.0030.001819%Not Available
Atrophy08.03.04.0010.000909%Not Available
Autoimmune hepatitis09.01.07.019; 10.04.09.0010.000202%Not Available
Azotaemia20.01.01.0010.000303%Not Available
Back disorder15.03.01.0140.001414%Not Available
Back pain15.03.04.0050.023036%
Bacterial disease carrier11.07.03.0010.000303%Not Available
Barrett's oesophagus07.11.03.0020.000909%Not Available
Bartholin's cyst16.04.04.003; 21.08.03.0010.000303%Not Available
Basal cell carcinoma16.03.02.001; 23.08.02.0010.003334%Not Available
Basedow's disease05.02.02.003; 06.09.04.003; 10.04.08.0040.000303%Not Available
Benign breast neoplasm16.14.01.005; 21.05.01.0090.000707%Not Available
Benign neoplasm of skin16.26.01.006; 23.10.01.0060.000505%Not Available
Benign prostatic hyperplasia21.04.02.0010.000808%Not Available
Bile duct stone09.02.02.0030.000303%Not Available
Biopsy breast13.20.02.0040.001010%Not Available
Bladder cancer16.08.01.001; 20.03.04.001--Not Available
Bladder dilatation20.03.01.0070.000202%Not Available
Bladder discomfort20.02.02.0190.000202%Not Available
Bladder neoplasm16.08.03.002; 20.03.04.0020.000404%Not Available
Bleeding time prolonged13.01.02.0020.000202%Not Available
Blepharitis06.04.04.001; 23.03.04.0120.000808%Not Available
Blindness06.02.02.001; 17.17.01.0030.001010%Not Available
Blindness unilateral06.02.02.009; 17.17.01.0160.000404%Not Available
Blister12.01.06.002; 23.03.01.0010.001516%Not Available
Blood albumin decreased13.09.01.0010.000505%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 49 Pages